What “they” could refer to, and how it would affect Vioxx’s approval
Your question is missing context on who “they” are. With Vioxx (rofecoxib), the approval process could be affected by two broad categories of “they” that people commonly mean:
- Regulators (FDA) and what evidence they reviewed: If you mean new studies, safety findings, or analyses presented to the FDA during review, those could change approval decisions or label requirements.
- Companies or lawsuits (e.g., challengers) impacting the approval path: If you mean legal actions or patent/market threats, those typically affect commercial entry or exclusivity rather than whether FDA approved a drug in the first place.
If you mean “new safety concerns” — did they change the approval decision?
Vioxx was approved by the FDA based on the evidence available at the time of review. Later safety findings and controversy did affect its market fate (including withdrawal and FDA actions) more than the original approval step, because approval typically depends on the data submitted for that review cycle.
If you mean “patent or litigation threats” — did those affect FDA approval?
Patent litigation and exclusivity disputes generally do not control FDA approval for an already-approved drug. They can influence whether competitors can market a version, but they don’t usually stop the FDA from approving the original product (or change the original approval) unless a specific regulatory pathway is at issue.
What I need to answer precisely
Who is “they” in your question? For example:
- FDA reviewers?
- A competitor filing something?
- A company submitting additional data?
- A specific lawsuit or public health group?
- Studies reported at a particular time?
If you tell me who “they” refers to (and, if possible, the drug/date/context you mean), I can give a direct yes/no with the relevant timeline.